EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review

Sarah A L Price iD, Alison Nankervis

Archives of Gynecology and Obstetrics · 07.01.2025 · 311 (5) · 1241-1247

DOI: 10.1007/s00404-024-07849-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 07.01.2025. Verfasst von Sarah A L Price und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Grattan St, Parkville, VIC, 3050, Australia. sarah.price@unimelb.edu.au. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Preconception Care, Pregnancy Complications. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Ramsay Hospital Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced the risk of adverse health outcomes for women with obesity and their offspring, resulting in a shift in focus to the pre-conception period. Although not yet recognised in most international weight management guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are being increasingly used for weight management prior to conception.

Methods

A literature search of PubMed, Medline, and Embase databases identified relevant articles describing the use of GLP-1 RAs prior to and during pregnancy. Papers were selected based on relevance and originality, with clinical trials, large observational studies and meta-analyses being preferentially included.

Results

This narrative review summarises the mechanism of action of GLP-1 RAs and the clinical effects observed in non-pregnant adults. It synthesises the available data from human and animal studies regarding the safety and efficacy of GLP-1 RAs prior to pregnancy, and the consequences of inadvertent drug exposure in early pregnancy. In considering the need to balance the risks of metabolic disease with the risks posed by inadvertent drug exposure, it highlights the areas where further research is needed to guide clinical decision-making.

Conclusion

GLP-1 RAs may have a role in facilitating weight loss and improving the metabolic health of women prior to pregnancy. However, there is currently insufficient evidence to demonstrate that the use of this class of drugs prior to pregnancy improves pregnancy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityPreconception CarePregnancy ComplicationsHypoglycemic AgentsHumansFemalePregnancyExenatideAnimals

Stichwörter der Autor:innen

GLP-1 RAObesityPregnancyPregnancy outcomesWeight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsExenatide

Autor:innen und Institutionen

  • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Grattan St, Parkville, VIC, 3050, Australia. sarah.price@unimelb.edu.au.
  • Department of Obstetric Medicine, Royal Women's Hospital, Flemington Rd, Parkville, VIC, Australia. sarah.price@unimelb.edu.au.
  • Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Grattan St, Parkville, VIC, Australia. sarah.price@unimelb.edu.au.
  • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Grattan St, Parkville, VIC, 3050, Australia.
  • Department of Obstetric Medicine, Royal Women's Hospital, Flemington Rd, Parkville, VIC, Australia.
  • Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Grattan St, Parkville, VIC, Australia.

ORCID-Profile: Sarah A L Price

Förderung

  • National Health and Medical Research Council
  • Ramsay Hospital Research Foundation

Zitieren

APA

Price, S. A. L., & Nankervis, A. (2025). Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review. Archives of Gynecology and Obstetrics, 311(5), 1241-1247. https://doi.org/10.1007/s00404-024-07849-9

Vancouver

Price SAL, Nankervis A. Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review. Archives of Gynecology and Obstetrics. 2025;311(5):1241-1247. doi:10.1007/s00404-024-07849-9

BibTeX
@article{Price2025,
  author = {Price, Sarah A L and Nankervis, Alison},
  title = {Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2025},
  volume = {311},
  number = {5},
  pages = {1241--1247},
  doi = {10.1007/s00404-024-07849-9}
}
Kostenlos starten →